Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells

SIMPLE SUMMARY: Poly(ADP-ribose) polymerases inhibitors (PARPis), including olaparib, have been recently approved for ovarian carcinoma treatment and PARPi resistance has already been observed in the clinics. With the aim of dissecting the molecular mechanisms of PARPi resistance, we generated olapa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiappa, Michela, Guffanti, Federica, Anselmi, Martina, Lupi, Monica, Panini, Nicolò, Wiesmüller, Lisa, Damia, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997432/
https://www.ncbi.nlm.nih.gov/pubmed/35406579
http://dx.doi.org/10.3390/cancers14071807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997432/
https://www.ncbi.nlm.nih.gov/pubmed/35406579
http://dx.doi.org/10.3390/cancers14071807

Ejemplares similares